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Abstract
The genetics of ovarian cancer are a complex, ever evolving concept that presents hurdles 
in classification, diagnosis, and treatment in the clinic. Instead of common driver muta-
tions, genomic instability is one of the hallmarks of ovarian cancer. While ovarian cancer 
is stratified into different clinical subtypes, there still exists extensive genetic and progres-
sive diversity within each subtype. In high-grade serous ovarian cancer, the most com-
mon subtype, TP53 is mutated in over 90% of all patients while the next most common 
mutation is less than 20%. However, next-generation sequencing and biological statistics 
have shown that mutations within DNA repair pathways, including BRCA1 and BRCA2, 
are common in about 50% of all high-grade serous patients leading to the development 
of a breakthrough therapy of poly ADP ribose polymerase (PARP) inhibitors. This is just 
one example of how a better understanding of the complex genetic background of ovar-
ian cancer can improve clinical treatment. A thorough review of ovarian cancer genetics 
and the effect it has on disease development, diagnosis, progression, and treatment will 
enhance the understanding of how to better research and treat ovarian cancer.
Keywords: genetics, subtypes, pathogenesis, BRCA1, BRCA2, TP53, risk factors
1. Introduction
Ovarian cancer is a generic term used to classify cancers involving the ovaries though they 
can arise from many different cell types within the Müllerian compartment. Ovarian cancer 
presents as a distinct subset of cancers with a wide variety of genomic variation (e.g., somatic 
TP53 mutations, germline BRCA1/2 mutations, copy number gains in BRAF, CCNE1, TERC, 
TERT, and copy number loss of RB1 and/or PTEN) as demonstrated through a Pan-Cancer 
analysis using The Cancer Genome Atlas (TGCA) database (Figure 1). The pathogenesis and 
the debate of cellular origins of ovarian cancer will be discussed in Section 4.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Ovarian cancer is a pathological and genetically diverse disease that presents many hurdles 
towards clinical detection and treatment. These clinical barriers have prevented significant 
improvement in patient survival for the past three decades. The heterogeneity of ovarian can-
cer is one of the driving factors limiting clinical progress. In this chapter, we will discuss the 
diversity of ovarian cancers and how these genetic factors effect clinical detection, progres-
sion, and treatment. A better understanding of the genetic differences in ovarian cancer will 
open up new areas for research and treatment.
Ovarian cancer can be classified into subclasses based on pathological and genetic observations. 
Each subclass has distinct genetic alterations, disease pathogenesis, tumor progression, and 
survival outcomes in response to therapy. Not only does each subclass behave differently, het-
erogeneity within specific subclasses presents challenges in regards to treatment options, drug 
resistance, and overall clinical response. Genetic diversity has greatly limited the development 
of targeted therapies, which have been successful in other cancers, such as HER2 amplified 
breast cancers (trastuzumab, Herceptin®), BCR-ABL fusion in chronic myelogenous leukemia 
(CML) or KIT mutant gastrointestinal stromal tumor (imatinib mesylate, Gleevec®), and BRAF 
V600E mutant melanoma, vemurafenib (Zelboraf®). However, understanding genetic vulner-
abilities such as deficiencies in homologous DNA repair prompted the development of poly 
Figure 1. Common genetic alterations in ovarian cancer represented across pan-Cancer analysis from the TCGA. Bar 
graphs depict % of cases with mutations (green), amplification (red), and/or deletion of commonly dysregulated genes 
across a panel of cancers in the TCGA.
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ADP ribose polymerase (PARP) inhibitors, a breakthrough in the treatment of specific ovarian 
cancer patients.
Finally, we will discuss genetic and lifestyle factors that can contribute to the development 
or progression of ovarian cancer. Since ovarian cancer is difficult to detect at early stages, 
knowing genetic and lifestyle risk factors for the development of the disease is critical. In 
fact, studying familial breast and ovarian cancer led to the discovery of inherited mutation 
in either BRCA1 or BRCA2 and improved detection of patients at risk for both cancers. While 
germline BRCA1/2 mutations are two of the highest risk factors for developing ovarian, other 
genetic and lifestyle factors have been shown to influence the risk of disease development. A 
more thorough understanding of the risks of ovarian cancer is needed to stratify the chances 
of developing ovarian cancer for each patient.
2. Classification of ovarian cancer
Ovarian cancers of epithelial cell origin account for more than 85% of all ovarian tumors 
when compared to tumors that arise from germ, epidermoid, stromal, and border cells [1]. 
Since EOCs are the most common and deadly form of ovarian cancer, we will refer to EOC 
as ovarian cancer for the remainder of this chapter and primarily discuss ovarian cancers of 
epithelial origin [2, 3]. Typically, EOC is classified into five different histological subtypes: 
high-grade serous (HGS), low-grade serous (LGS), endometrioid, clear cell and mucinous 
[3, 4] (Table 1). Low-grade and high-grade disease can typically be distinguished based on 
the extent of nuclear atypia and mitosis [5]. Low-grade tumors are slower growing, more 
genetically stable and do not respond to chemotherapy as well as the faster growing, gnomi-
cally instable high-grade tumors [6–8]. High-grade serous carcinomas are the most common 
ovarian cancer subtype (more than 70%) followed by endometrioid, clear cell and low-grade 
serous [9]. Mixed ovarian cancers that represent more than one subtype are more rare, 
accounting for less than 1% of all ovarian cancers [10, 11]. Globally, each subtype follows a 
similar distribution of incidence outside of Asia, where clear cell and endometrioid tumors 
are more frequent compared to other locations [12]. Each subtype behaves as a discrete dis-
ease with differences in presentation, progression, mutation profile, association with heredi-
tary cancer syndromes, and response to chemotherapy (Table 1) [13]. The 10-year survival 
for each subtype can be influenced by each of these factors and ranges from mucinous (87%), 
endometrioid (59.7%), clear cell (58.7%), to serous (24.4%) [14, 15].
Each subtype has distinct histological protein expression patterns, mutations and even epigen-
etic signatures. Further classification based on molecular profiles may provide insights into 
improving therapy selection [16, 17]. Recent studies have helped to further stratify the genomic 
differences between each subtype where 12 different loci contribute to the susceptibility of 
serous (3q28, 4q32.3, 8q21.11, 10q24.33, 18q11.2, 22q12.1, 2q13, 8q24.1 and 12q24.31), muci-
nous (3q22.3 and 9q31.1) and endometrioid (5q12.3) subtypes of ovarian cancer [18]. Molecular 
classification has been shown to stratify low-grade diseases into separate clusters, whereas 
high-grade diseases have less genetic separation [19–21], indicating early pathogenesis of the 
disease might be the best time to molecularly phenotype or develop targeted therapies.
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Within each subclass ovarian cancers are diagnosed and staged after primary cytoreduc-
tive surgery which attempts to remove any visible mass within the peritoneal cavity. The 
International Federation of Gynecology and Obstetrics (FIGO) have established guidelines for 
the staging of ovarian cancer. These guidelines are established based on disease localization 
from ovaries only (Stage I), pelvic extension (Stage II), peritoneum spread (Stage III), to dis-
tant metastases (Stage IV). While the 5-year relative survival for localized disease is over 90%, 
the majority of patients are diagnosed with regional (15%) or distant (60%) disease where the 
5-year survival is 73% and 28.9% respectively [22]. While molecular characterization of each 
stage is still progressing, some data suggest there is a stepwise progressing in gene expression 
that could be exploited for enhanced staging [23].
In the next sections of this chapter we will discuss each subtype of ovarian cancer. We will focus 
primarily of specific genomic alterations, clinical pathogenesis, and responses to therapy.
2.1. High-grade serous tumors
High-grade serous tumors account for both the majority of ovarian cancer diagnoses and 
deaths [5, 9]. HGS tumors show a broad range of histological phenotypes with papillary, 
micropapillary, glandular, cribriform and trabecular structures involving columnar cells with 
pink cytoplasm [24, 25]. HGS is a separate disease from its LGS counterpart (and not different 
grades of the same neoplasm) and is identified by high mitotic index and high-grade nuclear 
features [5, 26] (Figure 2). HGS disease can be identified from other malignancies such as uter-
ine cancer and endometrioid cancer through positive staining in WT-1, p53, and p16 [27–31]. 
The majority of HGS tumors are diagnosed at late stages when a complete resection of the 
tumor is difficult. In fact, less than 5% of HGS cancers are diagnosed at a Stage 1 (when the 
tumor is confined to the ovaries). Finally, while extremely rare, there is some evidence to sup-
port the progression of LGS or borderline tumors into high-grade disease. These cases have 
been identified through concurrent mutations in KRAS and TP53 in both a borderline lesion 
and HGS carcinoma [32]. This progression could be due to a secondary mutation of TP53 in 
borderline or low-grade tumors [33].
HGS tumors are associated with genomic instability [2, 34] since almost all (>95%) high-grade 
serous cancers have somatic TP53 mutations and over half have homologous DNA repair 
Sub Type Mutations Clinical Prognosis Frequency
High-grade serous TP53, BRCA1, BRCA2, CDK12 Often diagnosed at late stage and 
chromosomally unstable.
~65%
Low-grade serous BRAF, KRAS, NRAS, ERBB2 Often diagnosed in younger patients, less 
aggressive, gnomically stable.
~5%
Endometrioid PTEN, CTNNB1, PPP2R1α, 
MMR deficient
Favorable prognosis and response to 
chemotherapy.
~20%
Clear cell carcinoma PIK3CA, KRAS, PTEN, 
ARID1A
Low response to chemotherapy and 
intermediate prognosis.
~5%
Mucinous KRAS, HER-2 amplification Low response to chemotherapy. ~5%
Table 1. Subtypes of ovarian cancer.
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pathway deficiencies mainly represented by defects in BRCA1, BRCA2, or related proteins 
[35–38]. Many of these genomic alterations are similar to basal-like breast cancer, opening 
the opportunity for comparative studies [39]. In fact, when compared to other cancers HGS 
ovarian cancer had the most genomic instability when comparing copy number alterations to 
mutation rates [40]. Other genetic alterations that have been identified in HGS disease include 
cyclin E1 (CCNE1) amplifications. CCNE1 amplification in HGS disease is associated with 
poor prognosis and platinum resistance [41]. Likewise, HGS genomic instability leads to inac-
tivation of tumor suppressor genes through gene breakage [42]. Loss of expression of PTEN in 
tumor specific cells is predictive of poor patient survival in ovarian cancer [43].
To provide an example of this, we utilized data available through TCGA to demonstrate 
genetic aberrations within 34 common cell cycle control genes from 316 HGS ovarian cases 
with complete mutation, copy number alteration, and mRNA data [44] (Figure 3). While some 
alterations were fairly consistent across patient samples (such as up-regulation or amplifica-
tion of MYC in ~30% of cases, down-regulation of RBL2 in ~25% of cases, and up-regulation 
or amplification of CCNE1 in ~20% of cases) the remaining 31 queried genes had between 3 
and 29% alteration rates of which there was little discernable pattern. As a comparison, TP53 
is shown to be altered in most of the cases.
Examples such as this demonstrate just how difficult high-grade EOC is to treat with single 
molecularly-targeted therapies [45, 46]. However, one of the major breakthroughs for the 
treatment of ovarian cancer has been the development and FDA approval of PARP inhibi-
tors, olaparib (Lynparza), rucaparib (Rubraca), and niraparib (Zejula). Specifically, in BRCA 
deficient or other homologous repair deficient cells, PARP inhibitors induce the error prone 
DNA repair pathway non-homologous end joining [47]. Therefore, PARP inhibitors were 
investigated for efficacy in ovarian cancer due to the high number of patients with BRCA and/
or homologous recombination (HR) deficient tumors [48]. Rucaparib, an oral PARP-1, −2 and 
−3 inhibitor, has been approved for treatment in patients with BRCA mutations (somatic or 
germline) who have received at least two prior chemotherapy treatments [49, 50]. Another 
PARP inhibitor, niraparib, was approved in early 2017 for the maintenance treatment of adult 
patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, regard-
less of the BRCA mutation status. However, in the Phase III trial of niraparib, the progression 
Figure 2. Representative H&E staining of high-grade serous ovarian carcinoma.
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free survival (PFS) was superior only for germline BRCA mutant patients when compared to 
standard of care (22 months vs. 9 months) versus BRCA competent patients compared to stan-
dard of care (9.3 months vs. 3.9 months) [51], indicating better activity in the BRCA deficient 
tumors. To address this limitation, our laboratory has shown that alisertib (MLN8237) can 
inhibit DNA double strand break repair as well as BRCA expression which sensitizes resistant 
Figure 3. Genetic Dysregulation in high grade serous ovarian cancer. Data from the TCGA showing mutation, copy 
number alteration, and mRNA dysregulation of 34 cell cycle control genes and TP53 alteration status (as a comparison) 
within 316 cases of high grade serous ovarian cancer demonstrates the overall heterogeneity of the disease.
Ovarian Cancer - From Pathogenesis to Treatment
cells to PARP inhibitors [52]. Using therapies to mimic different genetic phenotypes such as 
BRCAness has promising clinical application for ovarian cancer in trying to identify target 
therapies in a genetically diverse disease. Both of these therapies show that and understanding 
of the dynamic genes expressed in ovarian cancer can be used to mimic more sensitive disease 
(synthetic lethality) and improve therapy efficacy in the laboratory.
To add to this hurdle, while HGS tumors are initially responsive to platinum-chemotherapy, 
most patients’ tumors recur which are resistant to standard chemotherapy, thus limiting 
treatment options for these women. The deficiencies in DNA repair pathways associate with 
widespread copy number alterations and make HGS cancer initially sensitive to platinum-
based chemotherapy (and PARP inhibitors) but develop therapy resistance. Specifically the 
genomic instability can drive changes that reverse the initial sensitivity to PARP inhibitors 
through reversion of BRCA1/2 mutants to wild-type function [42, 53]. Similar to PARP inhibi-
tors, patients with BRCA mutations are initially more sensitive to chemotherapy; however, 
reversion of the BRCA1/2 mutations promotes cisplatin resistance [53, 54]. Further, specific 
expression of many different genes such as ABC1 [55–59], ABC2 [60, 61], and GSH1 [62, 63] 
correlate to disease progression and drug resistance. The expression of mesenchymal genes 
such as SNAIL, SLUG, and TWIST through the epithelial to mesenchymal transitions (EMT) 
promotes chemotherapy resistance [64, 65]. EMT is a dynamic cellular process that can be 
transferred from on cell to the next through many cellular pathways including extracellular 
vesicles [66, 67]. Since EMT is a dynamic process, therapies that reverse the process and pro-
mote the expression of epithelial genes are an intriguing area for drug development to reverse 
cell growth into more sensitive phenotypes [68]. The relative success of PARP inhibitors and 
lack of clinical efficacy of more specific targeted therapies shows the value of identifying and 
exploiting the underlining molecular vulnerabilities of ovarian cancer.
2.2. Low-grade serous and borderline tumors
Low-grade serous (LGS) account for approximately 10% serous tumors. LGS tumors are more 
common in younger patients with an average age at diagnosis of 55.5 years compared to 
62.6 years for their high-grade counterpart. LGS ovarian cancer is more commonly diagnosed 
at early stages, with bilateral involvement, and without invasive potential [69]. Patients with 
non-invasive tumors have a significantly higher 7-year survival (95.3%) compared to those 
with invasive tumors (66%) [70, 71]. LGS tumors appear with extensive papillary features and 
psammoma bodies, uniform round to oval nuclei, evenly distrusted chromosomes, and ~10 
mitoses/HPF (Figure 4).
When compared to high-grade disease, LGS tumors are typically slower growing and have 
more frequent mutations in KRAS, BRAF, and ERBB2, and tend to lack TP53 mutations [72–74]. 
Mutations in KRAS, BRAF, and ERBB2 in LGS tumors are mutually exclusive. However, each 
gene mutation are signatures of activated mitogen-activated protein kinase (MAPK) path-
ways. MAPK activation is higher in LGS compared to HSG and correlates with paclitaxel sen-
sitivity and an improved 5-year survival [75]. Along with having functional p53, LGS tumors 
have a more stable genome with less rearrangements, mutations, and tumor heterogeneity 
[76]. However, due to more competent DNA repair pathways, LGS tumors do not respond 
Ovarian Cancer Genetics: Subtypes and Risk Factors
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to front-line chemotherapy as well as HGS tumors [77]. Consequently, a patient with optimal 
debulking surgery with minimal residual tumor is the best predictor of survival [78]. The 
involvement of MAPK regulation of cell cycle is thought to be strongly associated with LGS 
chemoresistance [75], but in turn provides a potential subpopulation for targeted therapeutic 
development [79]. Selumetinib, a MEK1/2 inhibitor, showed some activity in recurrent LSG, 
leading to further investigation of MAPK pathway inhibitors for the treatment of LSG [80].
LGS tumors are thought to be borderline tumors formed step-wise from the ovarian surface 
[73]. Borderline tumors are epithelial tumors that appear to represent and intermediates step 
between benign cystadenomas and adenocarcinomas with histological features such as cellu-
lar atypia without stromal invasion. Progression of LGS tumors from borderline tumors is also 
thought be from recurrence of undetected borderline tumors [81–83]. While borderline tumors 
can be diagnosed as either serous or endometrioid the majority of such cases are diagnosed as 
serous tumors [26]. Borderline tumors account for ~15% of all ovarian cancer diagnoses with a 
large percent of cases diagnoses at early stage (~75%) and a high rate of overall survival [84]. 
Diagnosis at an early age (mean age of ~45 years) and minimal invasive disease are primary 
factors for the favorable survival [26]. While rare, invasive borderline tumors (Stages II-IV) 
account for the majority of deaths in borderline tumor patients [85]. Borderline tumors have 
a similar activation of MAPK compared to LGS tumors [75], but a higher frequency in BRAF 
mutations [86]. BRAF mutations are more common in early stage tumors as well as in late stage 
tumors that do not recur in the patient [87]. However, it is possible many LGS progress inde-
pendent of borderline tumors and the pathogenesis of LGS requires further elucidation [88].
2.3. Endometrioid tumors
Endometrioid tumors account for about 10–20% of all ovarian cancers. Their morphology is 
described as having a smooth outer surface with solid, cystic areas inside while the pathological 
phenotype involves high amounts of proliferative cells that resemble squamous or endometri-
oid differentiations with secretory cell features. Tumors contain cystic spaces lined by gastro-
intestinal-type mucinous epithelium with stratification and may form filiform papillae with 
at least minimal stromal support. Histologic review find that endometrioid tumors possess 
Figure 4. Representative H&E staining of low-grade serous ovarian carcinoma.
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nuclei that are slightly larger than cystadenomas; mitotic activity is present; goblet cells and 
sometimes Paneth cells (most commonly found in the small intestine) are present, but stromal 
invasion is absent [89, 90] (Figure 5). Endometrioid ovarian tumors are histologically similar to 
endometrial neoplasms. In fact, approximately one third of all endometrioid cases experience 
synchronous endometrial carcinoma or endometrial hyperplasia. This is not surprising given 
that endometrioid tumors are believed to arise from endometrial precursor cells and/or trans-
formed endometrioses, possibly from back flow during menstruation that implants onto the 
ovarian surface epithelium [91–95].
The 5-year survival rate for endometrioid tumors is between 40 and 80%, and the 10-year 
survival is promising at~60%. This is mostly due to early stage presentation of the disease; 
however, there is no survival difference when matched with serous patients of the same age 
and stage of diagnosis [96, 97]. Likewise, with serous tumors, endometrioid tumors can be 
both high- and low-grade with similar growth patterns distinguishing the two [98]. High-
grade endometrioid tumors are very similar to HGS tumors in terms of genome instability 
and response to chemotherapy [99]. The primary treatment regimen consists of surgical deb-
ulking followed by platinum-based chemotherapy. Mutation profiles of endometrioid tumors 
reveal frequent activating mutations in CTNNB1 and PIK3CA [100, 101], as well as ARID1A 
(which helped link their origin to endometriosis) [102]. PTEN is altered in ~20% of endome-
trioid tumors, and to a lesser extent KRAS and BRAF [103, 104]. Given this mutational profile, 
it has been hypothesized that a subset of endometrioid tumors may be responsive to mTOR 
inhibitors; however, results of Phase I and II trials have shown minimal increases in overall 
response rate [105]. Ongoing studies emphasize a need for better molecular screening to iden-
tify individuals who could potentially benefit from a limited number of targeted therapies.
2.4. Mucinous ovarian cancer
Mucinous ovarian cancer (MOC) are primarily unilateral, can be very large (mean size of 10 cm 
and can range up to 48 cm) [106–108], and are diagnosed at early stages (most are stage I or II). 
Invasive disease accounts for less than 10% of all MOC cases [108, 109]. Mucinous ovarian tumors 
are rare when compared to other subtypes with reports of the overall incidence ranging from 
Figure 5. Representative H&E staining of endometrioid ovarian cancer.
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~12% [110] to as low as 3% [3, 111]. Patients with invasive disease (FIGO Stage III or IV) have 
higher risk of death and shorter survival than patients with early disease (FIGO Stage I or II) [112]. 
The pathological definition of MOC dictates intracytoplasmic mucin is mandatory, although 
many mucinous tumors lack obvious apical mucin in large parts of tumor, thereby imparting an 
endometrioid appearance. Mucinous tumors are often heterogeneous contain endocervical-like 
or intestinal-like cells with gastric superficial/foveolar and pyloric cells, enterochromaffin cells, 
argyrophil cells, and Paneth cells (Figure 6). While cytokeratin 7 and 20 staining is used to define 
MOC pathologically, it is limited in distinguishing primary ovarian tumors from secondary 
metastases of gastrointestinal tumors [113, 114]. Secondary pathological markers such as SATB2, 
CDX2, and PAX8 have potential to help diagnose MOCs [115–117].
While the overall survival for mucinous ovarian disease is high due to the majority of cases 
being diagnosed at early stage, invasive disease has a worse clinical outcome [118] and low 
response rates to chemotherapy due to the high expression of genes involved in drug resistance, 
including the ABC transporters [119]. Mucinous disease is mostly thought to originate from the 
gastrointestinal tract [120], though the molecular mechanisms of the disease are still not fully 
elucidated. KRAS mutations, which are found in other ovarian cancer subtypes, are the most 
common genetic alterations found in MOC [29, 121, 122], followed by HER2 amplifications 
[123]. Other mutations such as BRAF, TP53, and CDKN2A have been reported in MOC [124].
Extensive clinical studies of MOC are difficult to perform due to low number of cases and 
complex diagnosis and lead to early trial terminations such as GOG241 [125]. Small trials have 
shown that HER2 amplifications in recurrent MOC are a potential therapeutic target with 
trastuzumab [126]. While most ovarian cancer trials of HER2 inhibitors have shown limited 
efficacy, the prevalence of HER2 amplifications in MOC disease to other subtypes makes it a 
prospect for preselection if enough patients can be recruited [127].
2.5. Ovarian clear cell carcinoma
Ovarian clear cell carcinoma (CCC) accounts for approximately 5% of all ovarian cancer patients in 
the United States; however, it is more common in Asian women (~11%) than in African American 
Figure 6. Representative H&E staining of mucinous ovarian cancer.
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(~3%) or Caucasian (~5%) women [3, 128, 129]. CCCs are generally large (can grow over 15 cm), 
unilateral tumors that display only papillary, tubulocystic, and solid architectures with hobnail 
cells containing clear cytoplasm (Figure 7). While the pathogenesis of CCC is unknown, gene 
expression studies indicate clear cell ovarian cancer does not cluster with other ovarian cancers 
and more closely resembles lung cancers, endometriosis, and renal cell carcinoma [99, 130–132]. 
In terms of molecular mechanisms, CCCs are complex at the genomic level and can have muta-
tions in ARID1A, PIK3CA, KRAS and PTEN [133, 134]: ARID1A is mutated in ~50% and PIK3CA 
mutated in ~33% of patient tumor samples [102, 135]. In contrast, CCCs are usually wild-type for 
TP53 and have a lower frequency of BRCA1 and BRCA2 mutations [136, 137].
Clinically, CCCs are typically diagnosed at an early stage; however, they are less responsive 
to front-line platinum-based chemotherapy, especially at later FIGO stages. When compared 
to matched serous disease, early stage CCC (I-II) had a better overall survival than serous, but 
late stage CCC (III-IV) had a worse prognosis than both serous [138] and endometrioid adeno-
carcinoma [137]. Interestingly, some evidence suggests that drug response can be correlated 
to CD44-10v isoform expression [139]. Like endometrioid, clinical trials aimed at treating CCC 
include mTOR inhibitors, including a Phase II trial investigating the addition of temsirolimus 
to standard first-line chemotherapy (NCT01196429). Additionally, CCC is characterized by 
overexpression of the pro-inflammatory cytokine IL-6, which could prove to be an alternative 
therapeutic target [140].
3. Ovarian cancer pathogenesis
EOCs were, for years, believed to arise primarily from the ovarian surface epithelium. 
However, two novel hypotheses for the pathogenesis of HGS ovarian cancer have been pro-
posed. In the first mechanism, genetic alterations occurring within the normal ovarian surface 
epithelium or inclusion cysts which either proceed via a high-grade pathway with no perceiv-
able intermediate histology or a low-grade pathway encompassing several, benign and non-
invasive steps (Figure 8). This first hypothesis was established in the 1970s and proposed that 
Figure 7. Representative H&E staining of ovarian clear cell carcinoma.
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ovarian surface epithelial cells underwent repeated stress through multiple rounds of ovula-
tion, leading to inflammation, DNA damage, and the initiation of tumorigenesis [141]. This 
hypothesis was in part supported by evidence on the decreased risk of ovarian cancer with 
the use of oral contraceptives, which inhibit complete ovulation [142, 143]. Other evidence 
supported the correlation between the number of lifetime ovulation cycles and the increase 
in ovarian cancer incidence [144]. Likewise, ovarian cancers are rare in other primates which 
have fewer ovulations cycles than humans [145]. However, ovarian tumors are more common 
in hens which have been induced to frequently ovulate [146, 147]. To further study the inces-
sant ovulation theory, additional animal models will clearly be needed. In fact, Godwin and 
colleagues were some of the first investigators to establish ovarian surface epithelial cultures 
from rat and human ovaries and use model incessant ovulation in vitro as a mechanism for 
transformation and tumorigenesis [148–161]. Inactivation of p53 and Rb1 in mouse ovarian 
surface cells also led to tumorigenic transformation [162].
The second theory, which has gain much traction over the past decade, describes a progres-
sion model in which ovarian cancer precursors develop in the fimbria from occult serous 
tubal intraepithelial carcinoma (STIC), prior to metastasis to the ovary [163, 164]. Due to the 
aggressive nature of HGS tumors and the presence of early genomic instability, it is hypoth-
esized that HGS ovarian tumors are instead metastatic lesions from the fallopian tube epi-
thelial cells (Figure 8). To reduce the risk of HGS ovarian cancer in women BRCA mutation 
carriers it is beneficial to undergo a bilateral salpingo-oophorectomy (removal of both the 
ovaries along with the fallopian tubes) instead of just an oophorectomy (removal of only the 
ovaries) [165, 166]. The primary risk reduction for ovarian cancer following salpingo-oopho-
rectomy was found to be serous disease [167]. Not only did these studies suggest a fallopian 
origin for serous disease, the use of salpingo-oophorectomy for preventative treatment for 
high-risk patients gave researchers and pathologist tissue to study and search for early ovar-
ian cancer or precursor lesions. Microdissection of the fallopian tube epithelium following 
salpingo-oophorectomy from patients with a disposition to ovarian cancer showed lesions 
with BRCA and TP53 alterations that resemble HGS tumors [168–171]. To follow-up, exten-
sive evaluation of both the fallopian tube and ovarian surface from BRCA mutant patients 
also showed common precursor lesions in the fimbria and not the ovarian surface [164, 172–
174]. In genetic mouse models, conditional inactivation of commonly mutated ovarian cancer 
genes (BRCA1, TP53 and RB1) in ovarian surface epithelium cells leads to the formation of 
leiomyosarcomas and not HGSC following implantation into the mouse bursal sack [175]. 
Along with genetic alterations, fallopian lesions from BRCA patients showed gene expression 
profiles that mimicked HGS cancers [176]. Immortalization of human fallopian tube secretory 
epithelial cells (using hTERT and SV40 large T antigen) were transformed in vivo and in vitro 
by oncogenic RAS or MYC [177]. In contrast to ovarian surface epithelial cells, the inactiva-
tion of Brca, Tp53 or Pten in Pax8 over expressing mouse fallopian tubal secretory cells led to 
the development of HGSC [178]. Other genomic alterations common in HGS disease such 
as CCNE1 amplification and other copy number alterations are also found in STIC lesions 
and might be an early step in the progression of HGS ovarian cancer [179, 180]. For example, 
CCNE1 amplifications are common in both tubal lesions and HGS tumors, while centrosome 
amplification is more pronounced in HGS disease, indicating CCNE1 copy number gain is 
an early step in tumorigenesis that later promotes centrosome amplification [181]. However, 
some evidence exists to show an independent clonal evolution between tubular lesions and 
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the patient’s synchronous carcinoma, indicating small number of fallopian tube lesions may 
be micrometastases from uterine endometrioid carcinomas [182].
Other studies suggest a different route of the pathogenesis of cancers, where somatic stem 
cells undergo oncogenic mutation and create cancer stem cells that populate tumors [183–187]. 
While this mechanism has been contested with evidence that cancer cell plasticity can induce 
a stem cell phenotype in cancer cells from differentiated tissue [188], understanding any stem 
cell niche in ovaries and fallopian tubes may provide insight into the pathogenesis of ovarian 
cancer. Both the ovarian surface epithelium and fallopian tube epithelium have stem cell niches 
with cells with regenerative properties that could serves as progenitor cells for ovarian cancer 
[189–191]. Some evidence supports there could be a stem cell niche within the junction between 
Figure 8. Pathogenesis pathways of ovarian cancer. Schematic representation of the prevailing theories behind ovarian 
cancer development.
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the ovarian surface the fallopian tube that helps repair the damage to the ovarian surface fol-
lowing follicle release [192]. Notch and Wnt, canonical stem cell pathways, have been shown 
to regulate differentiation in fallopian tube organoids and could contribute to fallopian tube 
repair [193]. Fallopian stem-like cells (CD44+ and PAX8+) can be isolated from distal end of the 
tube and are capable of clonal growth and self-renewal [194, 195]. Since these stem cell niches 
are located near the areas of ovarian and fallopian surface repair and precursor lesions they 
could be hotspots for the development of tumors from mutations in somatic stem cells. One 
recent study has shown that SOX2 is overexpressed in the fallopian tubes of patients with HGS 
disease and in BRCA1/BRCA2 mutation carries [196], indicating a possible stem cell precursor 
lesion. The role of stem cells in cancer and cancer progression will remain an influential area 
of research and can provide potential insight into ovarian cancer pathogenesis in the future.
Taken together, these data support that the pathogenesis of ovarian cancer is complex and 
thus contributes to the clinical difficulties in detecting the disease early. As our understanding 
of the genomic complexities of ovarian cancer continues to evolve and the cell type of origin 
is further defined, we should be able to use this information to improve detection at a time 
when disease can be cured and develop more precise therapies based on tumor profiling and 
precision medicine.
4. Ovarian cancer risk factors
4.1. Hereditary and genetic risk factors
Ovarian cancer risk is causally linked to both lifestyle and genetics. Firstly, hereditary ovar-
ian cancer accounts for approximately 5–15% of all cases [197] and are often diagnosed at an 
earlier age than sporadic disease. Furthermore, hereditary ovarian cancer tends to be of the 
high-grade serous subtype [198]. Therefore, patients with a first or second-degree relative with 
ovarian cancer have an increased risk of developing the disease (Figure 9). Specifically, there is 
a 2.5% risk of ovarian cancer in woman who report a sister EOC and a 9% risk if their mother 
has been previously diagnosed [197]. Familial ovarian cancer was first observed in Lynch syn-
drome (a disease associated with familial cancer due to inherited mutations in DNA repair 
machinery) in the 1970s [199, 200]. Multiple group and genomic mapping studies of breast and/
or ovarian cancer-prone families ultimately led to the identification of inherited mutations in 
BRCA1 [201] and later BRCA2 [202, 203]. The prevalence of BRCA1 or BRCA2 mutations in the 
populations has been estimated from 0.1–0.3%, and 0.1–0.7%, respectively, in Caucasians with 
European origins [204–206]. BRCA1 and BRCA2 are mutated in the germline of approximately 
9–13% patients with hereditary ovarian cancer [207–209]. For mutations in BRCA1, the esti-
mated average risk of ovarian cancers ranges from 20 to 50% [210–214]. For BRCA2, average 
risk estimates range from 5 to 23% [210–214]. Mutation-specific cancer risks have been reported 
that suggest ovarian cancer cluster region (OCCR) exist in both BRCA1 and BRCA2 [211, 215]. 
The prevalence and spectrum of mutations in BRCA1 and BRCA2 have been reported in single 
populations with the majority of reports focused on Caucasians in Europe and North America. 
The Consortium of Investigators of Modifiers of BRCA1 or BRCA2 (CIMBA) has assembled 
data on more than 26,000 BRCA1 and nearly 17,000 BRCA2 female mutation carriers from 69 
centers in 49 countries on six continents [216–222]. Ongoing studies by Tim Rebbeck and the 
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CIMBA consortium have comprehensively evaluated the characteristics of the over 1600 unique 
BRCA1 and more than 1700 unique BRCA2 deleterious (disease-associated) mutations found in 
the carriers [215]. The most common mutation types in these genes are frameshift mutations, 
followed by nonsense mutations. Therefore, understanding the type of mutations in BRCA1 or 
BRCA2 is important for risk assessment and determining medical management for patients. 
Most subtypes of ovarian cancer have been linked to BRCA1 or BRCA2 germline mutations but 
the development of HGS disease is the most common in these women carriers [223]. BRCA1 
and BRCA2 mutations are more common in Ashkenazi Jewish women [206, 224, 225] due to the 
three common Jewish founder mutations BRCA1 c.5266dup (5382insC) and BRCA1 c.68_69del 
(185delAG) and BRCA2 c.5946del (6174delT) which have long been used as a primary genetic 
screening test for women of Jewish descent. Other mutations that are relatively common in 
specific populations, referred to as founder mutations, can be used to in limited screening tests. 
For example, in Iceland, only two mutations have been reported: the common founder muta-
tion BRCA2 c.771_775del and the rarer BRCA1 c.5074G > A [226]. Despite having a higher risk 
for developing ovarian cancer, BRCA1/2 carriers have a better clinical outcome in terms of sur-
vival, with BRCA2 carriers having a more favorable outcome than BRCA1 carriers [54]. This 
Figure 9. Hereditary ovarian cancer and BRCA mutations. Pedigree descripting “BRCAness” and risk of ovarian cancer 
(top). The relative risk and prognosis for women with germline BRCA1/2 mutations.
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phenomenon is thought to be due to BRCA2 carriers responding better to platinum-based che-
motherapy [227]. However, the survival benefit decreases when examined over 10 years in HGS 
instead of 5 years [228]. Over time, this could be possible due to secondary intragenic mutations 
in BRCA1 and BRCA2 that restore the wild-type reading frame (conversion back to a functional 
BRCA) and losing favorable responses to chemotherapy [229].
As indicated, the location of the alteration within BRCA1 or BRCA2 may vary the risk of breast 
and ovarian cancer [215], but other studies including genome-wide association study (GWAS) 
have identified several single nucleotide polymorphisms (SNPs) associated with risk of ovar-
ian cancer for women in the general population [230]. Four of these SNP, i.e., rs10088218, 
rs2665390, rs717852, rs9303542, were associated with ovarian cancer risk in BRCA2 carriers, 
while two loci (rs10088218 and rs2665390) were associated with ovarian cancer risk in BRCA1 
carriers [217]. Inherited variants in other loci along with BRCA1 or BRCA2 mutations can bet-
ter predict the risk of either breast or ovarian cancer [220], indicating the need to better under-
stand concurrent sequence variants in women with deleterious BRCA1 or BRCA2 mutations. 
Concurrent mutations in 1p36 (WNT4), 4q26 (SYNPO2), 9q34.2 (ABO), and 17q11.2 (ATAD5) 
increased risk of all EOC subtypes while 1q34.3 (RSPO1) and 6p22.1 (GPX6) mutations 
increased the risk of serous ovarian cancer in BRCA carriers [231]. BRCA1 mutation carries 
can have reduced risk with concurrent sequence variants in CASP8, i.e., the D302H polymor-
phism [232]. Other genetic markers of risk, such as a variant allele of KRAS at rs61764370, 
referred to as the KRAS-variant, which disrupts a let-7 miRNA binding site in this oncogene, 
is associated with sporadic and familial ovarian cancer without BRCA1/2 mutations [233]. 
PALB2, encoding for a BRCA2 interacting protein, has increased promoter hypermethylation 
which results in decreased BRCA2 function and increased risk of ovarian cancer [234]. Recent 
data have shown that copy number variation in BRCA1 or BRCA2 mutation carriers can either 
increase the risk (OR2A) or decrease the risk (CYP2A7) of ovarian cancer [235]. A better under-
standing of secondary genetic alteration in BRCA1/2 mutant carriers can help determine the 
best clinical approach for managing the risk of disease.
Genetic risk factors outside of BRCA1 or BRCA2 mutations are not as well defined but often 
take place in genes involved in genomic integrity, most commonly DNA mismatch repair 
(MMR). SNPs in the TERT locus (rs2242652 and rs10069690) were associated with decreased 
telomere length and increased breast and ovarian cancer risk in BRCA mutation carriers 
[236]. A study that sequenced 12 genes for germline mutations in patients with ovarian can-
cer found BARD1, BRIP1, CHECK2, MREA11, MSH6, NMN, PALB2, RAD51C, or TP53 were 
mutated in 24% of the 360 patients enrolled [237]. Genes within the Fanconi anemia pathway 
are also associated with developing ovarian cancer, including RAD51C, RAD51D, and BRIP1 
[238, 239]. Other MMR genes have been associated with Lynch syndrome and ovarian cancer 
risk MLH1, PMS2, MSH2, and MSH6 [240–242].
4.2. Lifestyle risk factors
Environment and lifestyle also play a risk for developing both hereditary and sporadic ovarian 
cancer by either increasing or decreasing the lifetime risk of developing ovarian cancer. Like 
many cancers, age is a risk factor for ovarian cancer with most cases being diagnosed after the 
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age of 60 and the disease being extremely rare in patients under 40 years of age [243]. As previ-
ously discussed, surgical procedures such as tubal ligation, salpingectomy and unilateral or 
bilateral oophorectomy have varying degrees of success for the development of ovarian cancer 
by removal of the organs from which the cancer develops [244, 245]. In women with a BRCA1 or 
BRCA2 mutation, risk-reducing salpingo-oophorectomy (RRSO) decreased the lifetime risk of 
developing ovarian and breast cancer [165]. In a multicenter study, RRSO was associated with 
an 85% reduction in BRCA1-associated gynecologic cancer risk (hazard ratio [HR] = 0.15; 95% 
CI, 0.04 to 0.56), while protection against BRCA2-associated gynecologic cancer (HR = 0.00; 95% 
CI, not estimable) was suggested, its effect did not reached statistical significance [246]. The 
effects of RRSO can influence risk for each subtype given the nature of development from dif-
ferent tissues, hence why bilateral oophorectomy has a stronger influence on the development 
of HGS disease, since it is believed to develop from the fallopian tubes. Lifestyle factors which 
influence complete cycling during menstruation have some of the strongest effects on the risk 
of developing ovarian cancer. This hypothesis is attributed to incessant ovulation, in which the 
release of eggs from the ovary, the fusion on the fallopian tube and the rebuilding of the uterine 
wall all contribute to pathogenesis of ovarian cancer [141, 148]. One of the most common fac-
tors which can alter complete cycling is the use of oral contraceptives [243]. The increase in use 
of oral contraceptives could be attributed to the decrease in ovarian cancer in the last decade. 
The longer use of oral contraceptives has been shown to correlate to lower risk of developing 
ovarian cancer [247, 248]. The risk is reduced in both BRCA wild-type and mutant carriers [249] 
[250]. The risk of developing each subtype is decreased following oral contraceptive use, with 
the exception of clear cell carcinoma [251]. However, the associated side effects make it a poor 
treatment for prevention alone [252]. Another factor that can influence menstrual cycles and 
the risk of ovarian cancer is child birth [253], in specific the age at first birth and the number of 
births. In fact, it was discovered the risk of ovarian cancer decreases by approximately 10% for 
each 5-year increment in age at first birth [254]. Also, the number of births for a given women 
has additive decrease in the risk of ovarian cancer, decreasing by about 8% for each birth [255], 
while the age of each woman at the onset of menopause had a weak association [129, 256].
Other lifestyle factors can influence the risk of ovarian cancer, such as hormone replacement 
therapy, breast feeding, obesity and inflammation. Hormone replacement therapy increases 
the risk of developing ovarian cancer, depending on the therapy. For instance, the use of estro-
gen increases the risk of developing ovarian cancer by 22%, while the combination of estro-
gen and progesterone only has about a 10% chance of developing ovarian cancer [257–259]. 
A meta-analysis showed a similar risk for developing both HGS and endometrioid ovarian 
cancer in menopausal women [260]. Conversely, hormone replacement given for menopause 
symptoms may improve survival of ovarian cancer patients [261]. Another reproductive fac-
tor is breastfeeding, in BRCA1 mutant carriers breastfeeding lead to a reduced the risk of 
developing ovarian cancer [129, 243]. Meta-analysis also suggests the duration of lifetime 
breastfeeding is additive in reducing the risk of developing ovarian cancer [262]. Like many 
other cancers, cigarette smoking and alcohol consumption have at least some association with 
increasing the risk of developing ovarian cancer. Specifically, smoking is associated with an 
increased risk of developing clear cell and endometrial ovarian cancer but not serous [263]. 
Smoking increased the risk of mucinous ovarian cancer, but cessation returns can reduce the 
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risk over time [264] while heavy smoking (>10 packs per day) more than doubles the risk of 
developing ovarian cancer [265]. Alcohol consumption increased the risk of ovarian cancer, 
but seems to have an effect only in heavy drinkers. Consumption of more than 20 drinks 
per week is associated with increased risk [266] while with moderate use the risk is less pro-
nounced or significant [267, 268]. Obesity is associated with less common subtypes of ovarian 
cancer and not HGS [269] and the lifetime risk decreases with recreation physical activity 
[270]. Finally, inflammation increases the risk of developing ovarian cancer [271] while the 
use of aspirin was shown to reduce risk of developing ovarian cancer from between 20 and 
34% [272]. The use of other non-steroidal anti-inflammatory drugs (NSAIDs) showed a reduc-
tion in risk but was not significant.
5. Conclusion
Genetically, ovarian cancer is a heterogeneous and dynamic disease that presents several 
clinical and research challenges. While epithelial ovarian cancer is categorized pathologically 
into five basic subtypes, within each subtype exist genetic diversity that limits the develop-
ment of target therapies. To add to this complexity, one of the hallmarks of serous ovarian 
cancer is genomic instability, which is driven by frequent TP53 mutations and deficiencies in 
DNA repair pathways. While this genomic alterations have led to the development of break-
through therapies (PARP inhibitors), they also contributes to the dynamic cell growth and 
frequent genomic alterations and gene expression changes which contribute to the adapta-
tion to therapy. Likewise, the pathogenesis of ovarian cancer remains a debated field with the 
recent insights of progression of a subset of serous ovarian cancer from fallopian tube epithelial 
lesions. Progression from the fallopian tube means tumors detected on the ovarian surface 
are already metastatic disease, leading to quick progression and limited response to therapy. 
Overall, while many genetic and genomic abnormalities have been identified in ovarian can-
cer, additional discovers are needed to (1) improve early detection of the disease (at a time 
when current treatment might be curative), (2) further define molecular classifiers of response 
to therapy, and (3) develop therapies that will be more effective across or specific to the dif-
ferent molecular subtypes. Other than the very common TP53 mutation in high-grade serous 
ovarian cancer (96% of cases), which to date is undruggable, and the previously mentioned 
BRCA mutations (approximately 10–12% of ovarian cancers), only a small overall percentage of 
tumors from patients with this malignancy will be found to possess a specific causative muta-
tion that can be effectively targeted therapeutically. Therefore, implementation of genomic-
based medicine remains a challenge for the management of women with ovarian cancer.
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